Semaglutide Weight Management and Cardiovascular Risk Reduction

In the phase 2 trial, CagriSema appeared to have a safe and well- tolerated profile AES Severity of AEs Mild Moderate Severe Gastrointestinal adverse events Serious AES AEs leading to drug withdrawal CagriSema 2.4 mg (n = 31) Semaglutide 2.4 mg (n = 31) Cagrilintide 2.4 mg (n = 30) n % n % n % 21 67.7 22 71.0 24 80.0 18 58.1 13 14 45.2 16 36 41.9 20 66.7 51.6 13 43.3 0 0.0 1 3.2 1 3.3 18 58.1 10 32.3 10 33.3 0 0.0 2 6.5 4 13.3 0 0.0 1 3.2 0.0 Gastrointestinal adverse events were all mild or moderate in severity and the majority occurred during dose escalation GLP-1: Glucagon like peptide-1; AE: Adverse event Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg

View entire presentation